Letter to shareholders from CLINUVEL’s CEO
29 avr. 2022 01h20 HE
|
Clinuvel Pharmaceuticals Limited
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
13 juil. 2020 03h38 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...
Uptick Newswire Hosts CUV Ventures Corp. on the Stock Day Podcast to Discuss the Expansion of Their RevoluPAY App
15 févr. 2019 08h00 HE
|
CUV Ventures Corp.
PHOENIX, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CUV Ventures Corp. (TSX-V: CUV) (“the Company”), a multi-asset, multidivisional publicly traded Canadian company...
CLINUVEL delivers second positive financial result
29 août 2018 06h52 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 29, 2018 (GLOBE NEWSWIRE) -- EXECUTIVE SUMMARY – FINANCIAL YEAR 01 JULY TO 30 JUNE 2017/182016/17ChangeTotal Revenues$25.750m$16.984m52%Net profit before income tax...
CLINUVEL unveils new global positioning
19 févr. 2018 22h47 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 19, 2018 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA-DAX:UR9) (NASDAQ INTERNATIONAL DESIGNATION ADR:CLVLY) today released its new global Company...
Clinuvel to file new drug with FDA
18 juil. 2016 08h11 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, July 18, 2016 (GLOBE NEWSWIRE) -- Clinuvel Pharmaceuticals (ASX:CUV) (OTC:CLVLY) (XETRA:UR9) today announced that the US Food and Drug Administration (FDA) has...
US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP
06 juil. 2016 08h00 HE
|
Clinuvel Pharmaceuticals Limited
FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPPNDA filing allowed on a rolling basisFDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...